drugset / Trial / NCT02117115

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT02117115

Phase 0 Completed 21 enrolled Washington University School of Medicine
NaSingle-groupOpen-labelScreening

Summary

Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host disease. The primary endpoint is the feasibility and safety of contrast-enhanced abdominal CT in the early post-transplant period, as defined by the risk of contrast-related nephropathy or allergic reaction.

Timeline

Start
2014-06
Primary completion
2014-10
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ioversol Small molecule Other